stockrowKiniksa Pharmaceuticals International, plc
KNSA Healthcare Drug Manufacturers Specialty & Generic
Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.
- Revenue
- +58.1%
- EPS
- +142.2%
- Free cash flow
- +43.5%
Quarter to September 2026, against a year earlier
Follow KNSA
Alert me
Kiniksa Pharmaceuticals International, plc (KNSA) Shares outstanding
Kiniksa Pharmaceuticals International, plc's shares outstanding at the end of fiscal 2025 was $79.0M, up 10.6% from $71.4M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $84.9M. Over the past ten years it has ranged from $261.7K (fiscal 2016) to $79.0M (fiscal 2025) — the current reading is the highest in ten years. Kiniksa Pharmaceuticals International, plc ranks 34th of 81 Drug Manufacturers Specialty & Generic companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $79.0M | 10.58% |
| FY2024 | $71.4M | (0.69%) |
| FY2023 | $71.9M | 2.13% |
| FY2022 | $70.4M | 2.69% |
| FY2021 | $68.6M | 10.89% |
| FY2020 | $61.8M | 14.42% |
| FY2019 | $54.0M | 82.93% |
| FY2018 | $29.5M | 1,532.43% |
| FY2017 | $1.8M | 591.63% |
| FY2016 | $261.7K | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $84.9M | 1.82% |
| Jun 2026 | $83.4M | 1.20% |
| Mar 2026 | $82.4M | 4.34% |
| Dec 2025 | $79.0M | (1.32%) |
| 33 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| RDY Dr. Reddy's Laboratories Ltd compare | $833.3M |
| ELAN Elanco Animal Health Incorporated compare | $505.9M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $335.7M |
| HIMS Hims & Hers Health, Inc. compare | $231.7M |
| ALKS Alkermes plc compare | $176.4M |
| SUPN Indivior Pharmaceuticals Inc. compare | $122.0M |
| LQDA Liquidia Corporation compare | $101.4M |
| KNSA Kiniksa Pharmaceuticals International, plc | $84.9M |
| LNTH Lantheus Holdings, Inc. compare | $68.4M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on KNSA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement